Clinical trial · Observational
Screening of Cancer Patients to Assess Impact of COVID-19
A Research Platform to Screen Patients in Oncology and Assess Impact - RESPONSE
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Participants were not testing positive for COVID-19 and were not returning onsite for visits.
Summary
Brief summary (as posted)
The purpose of this study is to investigate the impact of COVID -19 in the cancer patient population. This will be done by looking at the rate of asymptomatic COVID-19 infection in cancer patients receiving cancer therapy, as well as their immune response. This is a sub-study of the U-DEPLOY study: UHN Umbrella Trial Defining Coordinated Approach to Pandemic Trials of COVID-19 and Data Harmonization to Accelerate Discovery. U-DEPLOY helps to facilitate timely conduct of studies across the University Health Network (UHN) and other centers.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Covid-19 | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nasopharyngeal (NP) swab | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Nasopharyngeal (NP) swabs
- description
- NP swabs: * At the time of consent * 3-6 weeks after starting cancer treatment (for patients whose treatment has yet not started) or 3-6 weeks after first swab (for patients already on treatment) * 3 months after second swab * 6 months after second swab * 12 months after second swab
- interventionNames
- Diagnostic Test: Nasopharyngeal (NP) swab
Primary outcomes (1)
- measure
- Rate of asymptomatic COVID-19 infection among cancer patients receiving cancer therapy
- timeFrame
- 12 months
Secondary outcomes (2)
- measure
- Rate of sero-conversion in cancer patients
- timeFrame
- 12 months
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients having an active malignancy who are planned to start therapy within 6 weeks of consent or are receiving a treatment for active malignancy. * The patient falls under either of the following categories: 1. Asymptomatic for COVID-19 (as per daily screening at the hospital entrance). 2. Has symptoms similar to those of COVID-19 (e.g. fever or flu-like symptoms such as cough or shortness of breath) that are assessed by the overseeing Investigator as being related to disease and unrelated to COVID-19 infection. Note: Patients who recovered from previous COVID-19 infection will be eligible. * No contraindication to performing a NP swab and blood work. Exclusion Criteria: * Any patients with fever, or flu-like symptoms assessed by the Investigator to be related or potentially related to COVID-19 infection will not be eligible. * Eastern Cooperative Oncology Group (ECOG) Performance Status of 3-4
References
Publications (0)
Data not yet available